T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Public Service Enterprise Group
PEG
$37.8B
| $45.3M | 0.01% |
678,836
+4,941
| +0.7% | +$303K |
|
|
INFA
752
DELISTED
Informatica
INFA
| $45.1M | 0.01% |
1,289,958
+73,655
| +6% | +$2.32M |
|
753
Pebblebrook Hotel Trust
PEB
$2.05B
| $45.1M | 0.01% |
2,928,450
-169,182
| -5% | -$2.66M |
|
754
DuPont de Nemours
DD
$19.5B
| $45M | 0.01% |
467,846
+10,075
| +2% | +$896K |
|
755
Intellia Therapeutics
NTLA
$1.66B
| $44.7M | 0.01% |
1,625,051
-209,092
| -11% | -$5.81M |
|
756
Vistra
VST
$49.1B
| $44.6M | 0.01% |
640,976
+94,842
| +17% | +$4.69M |
|
757
Encompass Health
EHC
$12.2B
| $44.6M | 0.01% |
540,519
+464,897
| +615% | +$34M |
|
758
VICI Properties
VICI
$29B
| $44.6M | 0.01% |
1,496,576
+29,145
| +2% | +$875K |
|
759
State Street
STT
$52.2B
| $44.6M | 0.01% |
576,333
+105,710
| +22% | +$7.84M |
|
760
Hamilton Lane
HLNE
$5.91B
| $44.5M | 0.01% |
394,806
+51,452
| +15% | +$5.81M |
|
761
Astera Labs
ALAB
$56B
| $44.5M | 0.01% |
+600,000
| New | +$44.5M |
|
762
Tenable Holdings
TENB
$4.41B
| $44.4M | 0.01% |
898,744
+7,258
| +0.8% | +$345K |
|
763
Cavco Industries
CVCO
$4.67B
| $44.2M | 0.01% |
110,832
-247
| -0.2% | -$87.5K |
|
|
PPL
764
PPL Corp
PPL
$26.8B
| $44.2M | 0.01% |
1,605,778
-2,039,483
| -56% | -$54.3M |
|
765
CG Oncology
CGON
$6.62B
| $43.6M | 0.01% |
+992,118
| New | +$40.5M |
|
766
Champion Homes
SKY
$5.23B
| $43.2M | 0.01% |
507,690
-248
| -0% | -$19.2K |
|
767
Teradyne
TER
$64.2B
| $43.1M | 0.01% |
382,264
-494,264
| -56% | -$51.5M |
|
768
Willis Towers Watson
WTW
$31B
| $42.6M | 0.01% |
154,973
+6,118
| +4% | +$1.61M |
|
769
Xylem
XYL
$28.1B
| $42.1M | 0.01% |
325,496
+1,732
| +0.5% | +$209K |
|
770
Delta Air Lines
DAL
$60B
| $41.8M | 0.01% |
872,836
+8,797
| +1% | +$364K |
|
|
ANSS
771
DELISTED
Ansys
ANSS
| $41.7M | 0.01% |
120,214
-96,670
| -45% | -$32.7M |
|
772
NetApp
NTAP
$40.2B
| $41.4M | 0.01% |
393,975
+111,439
| +39% | +$10.3M |
|
773
Diodes
DIOD
$4.48B
| $41.3M | 0.01% |
585,261
-19,373
| -3% | -$1.34M |
|
774
Beam Therapeutics
BEAM
$2.74B
| $41.2M | 0.01% |
1,246,189
+1,207,699
| +3,138% | +$37.6M |
|
775
Chemed
CHE
$7.02B
| $40.9M | 0.01% |
63,733
+32,752
| +106% | +$19.9M |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.